Dolutegravir,a Second-Generation Integrase Inhibitor for the Treatment of HIV-1 Infection

Abstract

Objective: To review the pharmacology, safety, and efficacy of dolutegravir, an integrase strand-transfer inhibitor (INSTI), and to discuss its role in the treatment of HIV-1-infected patients. Data Sources: PubMed articles indexed through August 2013 were identified using the search terms S/GSK1349572, dolutegravir, and integrase inhibitor. Information was also identified from the package insert, cited publication references, professional meeting abstracts, and the ClinicalTrials.gov registry. Study Selection and Data Extraction: English language articleswere selected for evaluation, with preference given to safety, efficacy, and pharmacokinetic studies conducted in HIV-1-infected patients. Data Synthesis: Dolutegravir is a new INSTI approved for combination treatment in HIV-1-infected adults and adolescent children. Four phase 3 studies provide the basis for current labeling in antiretroviral-naïve and antiretroviral-experienced adults. Results from these studies demonstrate that dolutegravir is noninferior in efficacy to raltegravir in antiretroviral-naïve patients and superior in antiretroviral-experienced patients. Superiority to efavirenz and darunavir/ritonavir was also demonstrated in antiretroviral-naïve patients. Dolutegravir is well tolerated, exhibits low potential for drug-drug interactions, and has a long serum half-life, allowing it to be administered once-daily in patients without preexisting INSTI resistance. Twice-daily administration is recommended in patients with known or suspected resistance mutations to first-generation INSTIs. Mild elevations in serum creatinine occur following dolutegravir initiation from inhibition of renal organic cation transporter 2 but do not reflect changes in glomerular filtration. Conclusions: Dolutegravir is the first second-generation INSTI and exhibits several advantages over current integrase inhibitors and other preferred antiretrovirals. Long-term efficacy and safety are needed to define dolutegravir's role in treatment.

Keywords

antiretroviral integrase inhibitor dolutegravir

Get full access to this article

View all access options for this article.

References

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed August 1, 2013.

Johns

Kawasuji

Weatherhead

. Carbamoyl pyridine HIV-1 integrase inhibitors 3: a diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem. 2013;56:5901-5916. doi:10.1021/jm400645w.

Fantauzzi

Turriziani

Mezzaroma

. Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl). 2013;5:29-40. doi:10.2147/HIV.S27765.

Pommier

Johnson

Marchand

. Integrase inhibitors to treat HIV/AIDS. Nature. 2005;4:236-248. doi:10.1038/nrd1660.

Hare

Smith

Métifiot

. Structural and functional analysis of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80:565-572. doi:10.1124/mol.111.073189.

Canducci

Ceresola

Boeri

. Cross-resistance profile of the novel Integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204:1811-1815. doi:10.1093/infdis/jir636.

Underwood

Johns

Sato

. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr. 2012;3:297-301. doi:10.1097/QAI.0b013e31826bfd02.

Nichols

Lazzarin

Maggiolo

. Phase 3 assessment of dolutegravir (DTG) 50 mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled (abstract TULBPE19). Paper presented at: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.

Min

Sloan

DeJesus

. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737-1745. doi:10.1097/QAD.0b013e32834a1dd9.

10.

Min

Song

Borland

. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-258. doi:10.1128/AAC.00842-09.

11.

Reese

Savina

Generaux

. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353-361. doi:10.1124/dmd.112.048918.

12.

Koteff

Borland

Chen

. A phase I study to evaluate dolutegravir’s effect on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75:990-996. doi:10.1111/j.1365-2125.2012.0440.x.

13.

Raffi

Rachlis

Stellbrink

. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735-743. doi:10.1016/S0140-6736(12)61853-4.

14.

Walmsley

Antela

Clumeck

. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results—SINGLE (ING114467) [abstract H-556b]. Paper presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 9-12, 2012; San Francisco, CA.

15.

Cahn

Pozniak

Mingrone

. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700-708. doi:10.1016/S0140-6736(13)61221-0.

16.

Tivicay (dolutegravir) tablet [product information]. Research Triangle Park, NC: GlaxoSmithKline; 2013.

17.

Song

Borland

Chen

. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56:1627-1629. doi:10.1128/AAC.05739-11.

18.

Cottrell

Hadzic

Kashuba

ADM

. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir [published online July 4, 2013]. Clin Pharmacokinet. doi:10.1007/s40262-013-0093-2.

19.

Letendre

Mills

Tashima

. Distribution and antiviral activity in cerebrospinal fluid (CSF) of the integrase inhibitor, dolutegravir (DTG): ING116070 week 16 results [abstract 178LB]. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, GA.

20.

Dooley

Sayre

Borland

. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among health subjects. J Acquir Immune Defic Syndr. 2013;62:21-27. doi:10.1097/QAI.0b013e318276cda9.

21.

Song

Borland

Chen

. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72:103-108. doi:10.1111/j.1365-2125.2011.03947.x.

22.

Song

Min

Borland

. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol. 2011;51:237-242. doi:10.1177/0091270010371113.

23.

Ford

Gould

Chen

. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744 [published online August 26, 2013]. Antimicrob Agents Chemother. doi:10.1128/AAC.01235-13.

24.

Song

Min

Borland

. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr. 2010;55:365-367. doi:10.1097/QAI.0b013e3181e67909.

25.

Song

Borland

Lou

. Effects of the enzyme inducers, tipranavir and efavirenz, on the pharmacokinetics of the integrase inhibitor, dolutegravir (S/GSK1349572) [abstract O-02]. Paper presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 13-15, 2011; Miami, FL.

26.

Song

Borland

Chen

. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects [abstract A1-1727]. Paper presented at: 51st Annual Interscience Conference on Antimicrobial Agent and Chemotherapy; September 17-20, 2011; Chicago, IL.

27.

Song

Borland

Min

. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55:3517-3521. doi:10.1128/AAC.00073-11.

28.

Patel

Song

Borland

. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66:1567-1572. doi:10.1093/jac/dkr139.

29.

van Lunzen

Maggiolo

Arribas

. Once-daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111-118. doi:10.1016/S1473-3099(11)70290-0.

30.

Raffi

Jaeger

Motta

. Dolutegravir is non-inferior to raltegravir and shows durable response through 96 weeks: results from the Spring-2 trial [abstract TULBPE17]. Paper presented at: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.

31.

Feinberg

Clotet

Khuong

. Once-daily dolutegravir is superior to darunavir/ritonavir in antiretroviral naïve adults: 48 week results from FLAMINGO (ING114915) [abstract H-1464a]. Paper presented at: 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.

32.

Eron

Bonaventua

Durant

. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207:740-748. doi:10.1093/infdis/jis750.

33.

ViiV Healthcare. Study assessing dolutegravir in HIV-1 infected subjects with virus resistant to raltegravir and/or elvitegravir (VIKING-4). http://clinicaltrials.gov/show/NCT01568892. Accessed November 7, 2013.

34.

Viani

Zheng

Alvero

. Safety and efficacy of dolutegravir (DTG; GSK1349572) in treatment-experienced HIV-1 infected adolescents: 24-week results from IMPAACT P1093 [abstract 172]. Paper presented at: IDWeek 2013; October 2-6, 2013; San Francisco, CA.

35.

Weller

Borland

Chen

. Pharmacokinetics (PK) and safety of dolutegravir (DTG) in subjects with severe renal impairment and healthy controls [abstract A1571]. Paper presented at: 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO.

36.

Patel

Song

Borland

. Pharmacokinetics of a dolutegravir pediatric granule formulation in healthy adult subjects [abstract 985]. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA.

37.

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) tablets [product information]. Foster City, CA: Gilead Sciences; 2012.

38.

Isentress (raltegravir) tablets [product information]. Whitehouse Station, NJ: Merck & Co, Inc; 2011.

39.

Post

Villanueva

Fisher

. Renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and cobicistat-boosted protease inhibitor regimens in HIV-1-infected patients with mild to moderate renal impairment [abstract TUPE280]. Paper presented at: 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.

40.

ViiV Healthcare. A study to determine safety and efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) in human immunodeficiency virus (HIV)-1 infected antiretroviral therapy (ART) naïve women (ARIA). http://clinicaltrials.gov/ct2/show/NCT01910402. Accessed November 7, 2013.